DIVIGEL (estradiol) by Convert Pharmaceuticals is estrogen receptor agonists [moa]. First approved in 2007.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
DIVIGEL is a transdermal gel formulation of estradiol, a small-molecule estrogen receptor agonist approved in 2007. It delivers estrogen systemically through the skin to treat menopausal symptoms and hormone deficiency. The product operates through classical estrogen receptor activation to restore circulating hormone levels.
This product is nearing loss of exclusivity with modest Part D spending (~$1M in 2023), indicating a contracted commercial footprint requiring defensive strategy and potential team restructuring.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on DIVIGEL at Convert Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked job postings and LOE approaching, DIVIGEL offers limited growth career opportunities; professionals should expect a defensive, shrinking commercial organization focused on market share retention and generic transition management. This assignment suits early-career professionals seeking stable, foundational experience in a mature product but provides limited visibility for advancement or specialty development.